-
1.发明授权Method and apparatus for separating ions of metallic elements in aqueous solution 失效在水溶液中分离金属元素的离子的方法和装置公开(公告)号：US07138643B2
公开(公告)日：2006-11-21
申请号：US10762990
申请日：2004-01-22
IPC分类号： G21G1/02
CPC分类号： G21G1/0005 , G21G2001/0078 , G21G2001/0094
摘要： Methods and apparatus for separating ions of metallic elements are provided. Preferred methods utilize a hydrophobic chelating extractant, such as an organophosphorus compound, adsorbed onto carbon or graphite fibers in the form of felt. Also described is a new thallium-201 generator that comprises a column containing an acidic organophosphorus extractant adsorbed on carbon or graphite fibers, and a yttrium-90 generator system comprised of two extraction columns designed to selectively absorb yttrium-90 at different pH, to enable the separation of yttrium-90 from strontium-90. The two columns are connected in series for stepwise separation. The yttrium-90 product is freed from residual strontium-90 and metal contaminants and can be eluted from the second column with dilute acid, acetate buffer, water or saline for labeling biological targeted molecules. The new generator system provides rapid and efficient separation of yttrium-90 and is amenable to both scale-up and automation. Also described is a new 99mTc generator that comprises a column containing an acidic organophosphorus extractant adsorbed on carbon or graphite fibers designed to selectively absorb 99Mo at a selected pH, to enable the separation of 99mTc from 99Mo.
摘要翻译： 提供了分离金属元素离子的方法和装置。 优选的方法利用以毡的形式吸附到碳或石墨纤维上的疏水螯合萃取剂，例如有机磷化合物。 还描述了一种新的铊-201发生器，其包含吸附在碳或石墨纤维上的酸性有机磷萃取剂的柱，以及由两个提取塔组成的钇-90发生器系统，其设计成在不同pH下选择性吸收钇-90，以使得 钇-90与锶-90分离。 两列串联连接以进行逐步分离。 钇-90产物不含残留的锶-90和金属污染物，并可用稀酸，乙酸盐缓冲液，水或盐水从第二柱洗脱，用于标记生物靶向分子。 新型发电机系统可快速有效地分离钇-90，并适应放大和自动化。 还描述了一种新的99m Tc发生器，其包括吸附在碳或石墨纤维上的酸性有机磷萃取剂的柱，其设计成在选定的pH下选择性吸收99％的Mo，以使得能够 从99％Mo分离99m Tc。
-
2.发明授权
公开(公告)号：US5053186A
公开(公告)日：1991-10-01
申请号：US416243
申请日：1989-10-02
CPC分类号： A61K51/02 , A61K51/1282 , G21G4/08
摘要： Water soluble irradiation targets are disclosed for the production of .sup.186 Re and .sup.188 Re. The irradiation targets are selected for both water solubility and absence of elements which would produce contaminating isotopes for medical therapeutic and diagnostic use. In one embodiment, .sup.186 Re or .sup.188 Re is produced by the direct irradiation of a water soluble irradiation target comprising .sup.185 Re or .sup.187 Re, respectively. Preferred targets for this purpose include aluminum perrhenate, lithium perrhenate and magnesium perrhenate. In another embodiment, a zirconyl tungstate generator comprising .sup.188 W for the production of .sup.186 Re is obtained by irradiating a soluble irradiation target comprising .sup.186 W, dissolving the irradiated target in aqueous solution, reacting the dissolved target with an aqueous solution comprising zirconyl ion to form an insoluble zirconium tungstate precipitate and disposing the precipitate in an elutable container. Preferred irradiation targets for this purpose include sodium tungstate and lithium tungstate. In each of the foregoing embodiments, the irradiation target is readily soluble in aqueous solution and may be used directly in solution form after irradiation, such as for ligand conjunction for medical diagnostic or therapeutic purposes, without cumbersome dissolution, neutralization, purification and other processing steps involving irradiated materials inherent in prior .sup.186 Re and .sup.188 Re production methods.
摘要翻译： 公开了用于生产186Re和188Re的水溶性辐射靶。 选择辐射目标是为了水溶性和不存在将产生用于医学治疗和诊断用途的污染同位素的元件。 在一个实施方案中，通过分别直接照射包含185Re或187Re的水溶性照射靶产生186Re或188Re。 用于此目的的优选靶标包括高铼酸铝，高铼酸锂和高铼酸镁。 在另一个实施方案中，通过照射包含186W的可溶性照射靶，将照射的靶溶解在水溶液中，使溶解的靶与包含锆离子的水溶液反应形成不溶性锆，得到包含用于制备186Re的188W的钨酸锆产生剂 钨酸盐沉淀并将沉淀物置于可洗涤容器中。 用于此目的的优选辐射靶包括钨酸钠和钨酸锂。 在上述各实施方案中，照射靶容易溶于水溶液，并且可以在照射后直接以溶液形式使用，例如用于医学诊断或治疗目的的配体连接，而不会繁琐的溶解，中和，纯化和其它加工步骤 涉及先前的186Re和188 Re生产方法固有的辐射材料。
-
3.发明申请ADVANCED ONCE-THROUGH PROCESSING FOR EXTRACTING MOLYBDENUM-99 FROM DEUTERIUM AND LOW ENRICHED URANIUM SOLUTIONS 审中-公开从高纯度和低浓度的铀溶液中提取钼99的高级处理公开(公告)号：US20110305308A1
公开(公告)日：2011-12-15
申请号：US12813417
申请日：2010-06-10
申请人： Fu-Min Su
发明人： Fu-Min Su
IPC分类号： G21G1/06
CPC分类号： G21G1/06 , G21G1/08 , G21G2001/0036
摘要： A large enhancement of neutron flux is realized when a primary target of D2O and H2O is contained in a vessel, is irradiated by an electron beam incident on a gamma converter and where the vessel is enclosed within a neutron reflector material including Nickel and Polyethylene. A very large enhancement of neutron flux is realized when a secondary target of LEU is mixed with the primary target resulting in a very large enhanced production of Molybdenum-99. The primary target and the secondary target is contained in cylindrical or spherical vessels. A process for extracting produced Mo-99 from the reaction vessel solution.
摘要翻译： 当容器中含有D2O和H2O的主要目标物时，通过入射在γ转换器上的电子束照射并将容器封闭在包括镍和聚乙烯的中子反射器材料内，实现了中子通量的大的增强。 当将LEU的二次靶与主要靶混合时，实现了中子通量的非常大的增强，导致非常大的增强的钼-99的生产。 主要目标和次要目标包含在圆柱形或球形容器中。 从反应容器溶液中提取生成的Mo-99的方法。
-
4.发明授权
公开(公告)号：US5145636A
公开(公告)日：1992-09-08
申请号：US717021
申请日：1991-06-18
CPC分类号： G21G4/08 , A61K51/02 , A61K51/1282
摘要： Water soluble irradiation targets are disclosed for the production of .sup.186 Re and .sup.188 Re. The irradiation targets are selected for both water solubility and absence of elements which would produce contaminating isotopes for medical therapeutic and diagnostic use. In one embodiment, .sup.186 Re or 188Re is produced by the direct irradiation of a water soluble irradiation target comprising .sup.185 Re or .sup.187 Re, respectively. Preferred targets for this purpose include aluminum perrhenate, lithium perrhenate and magnesium perrhenate. In another embodiment, a zirconyl tungstate generator comprising .sup.188 W for the production of .sup.188 Re is obtained by irradiating a soluble irradiation target comprising .sup.186 W, dissolving the irradiated target in aqueous solution, reacting the dissolved target with an aqueous solution comprising zirconyl ion to form an insoluble zirconium tungstate precipitate and disposing the precipitate in an elutable container. Preferred irradiation targets for this purpose include sodium tungstate and lithium tungstate. In each of the foregoing embodiments, the irradiation target is readily soluble in aqueous solution and may be used directly in solution form after irradiation, such as for ligand conjunction for medical diagnostic or therapeutic purposes, without cumbersome dissolution, neutralization, purification and other processing steps involving irradiated materials inherent in prior .sup.186 Re and .sup.188 Re production methods.
摘要翻译： 公开了用于生产186 Re和188Re的水溶性辐射靶。 选择辐射目标是为了水溶性和不存在将产生用于医学治疗和诊断用途的污染同位素的元件。 在一个实施方案中，通过直接照射包含185 Re或187Re的水溶性照射靶产生186Re或188Re。 用于此目的的优选靶标包括高铼酸铝，高铼酸锂和高铼酸镁。 在另一个实施方案中，通过照射包含186W的可溶性照射靶，将照射的靶溶解在水溶液中，使溶解的靶与包含锆离子的水溶液反应，形成不溶性锆，得到包含188W的188Re的氧化锆钨酸盐发生剂 钨酸盐沉淀并将沉淀物置于可洗涤容器中。 用于此目的的优选辐射靶包括钨酸钠和钨酸锂。 在上述各实施方案中，照射靶容易溶于水溶液，并且可以在照射后直接以溶液形式使用，例如用于医学诊断或治疗目的的配体连接，而不会繁琐的溶解，中和，纯化和其它加工步骤 涉及先前的186Re和188Re生产方法固有的辐射材料。
-
5.发明授权Stable therapeutic radionuclide compositions and methods for preparation thereof 失效稳定的治疗放射性核素组合物及其制备方法
公开(公告)号：US5679318A
公开(公告)日：1997-10-21
申请号：US342838
申请日：1994-11-21
IPC分类号： A61K51/04 , A61K51/10 , A61K51/12 , C07C227/08 , C07C271/22 , A61K51/00
CPC分类号： C07C271/22 , A61K51/0478 , A61K51/1093 , A61K51/12 , B82Y5/00 , C07C227/08 , A61K2123/00 , Y10S530/866
摘要： Stable therapeutic radionuclide compositions comprising, for example, .sup.186 Re, .sup.188 Re and .sup.131 I stably bound to a proteinaceous targeting moiety and suitable for human in vivo administration are disclosed. Stabilizing agents preferably comprise antioxidants and challenging agents, and combination of HSA with an antioxidant and/or challenging agent provides enhanced long term stability. Ascorbic acid is an especially preferred stabilizing agent, which provides stability of therapeutic radionuclide compositions at levels of at least about 90% for several hours up to several days.
摘要翻译： 公开了稳定的治疗放射性核素组合物，其包含例如稳定结合蛋白质靶向部分并适于人体内施用的186Re，188Re和131I。 稳定剂优选包含抗氧化剂和挑战性试剂，并且HSA与抗氧化剂和/或挑战性试剂的组合提供增强的长期稳定性。 抗坏血酸是一种特别优选的稳定剂，其在至少约90％的水平下提供几个小时至几天的治疗性放射性核素组合物的稳定性。
-
公开(公告)号：US6022966A
公开(公告)日：2000-02-08
申请号：US156565
申请日：1993-11-22
申请人： Linda M. Gustavson , Louis J. Theodore , Fu-Min Su , John M. Reno
发明人： Linda M. Gustavson , Louis J. Theodore , Fu-Min Su , John M. Reno
IPC分类号： A61K49/00 , C07K1/107 , C07K7/52 , C07D257/02
CPC分类号： C07K1/1077 , A61K47/48146
摘要： Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.
摘要翻译： 公开了与诊断和治疗剂的预靶向递送相关的方法，化合物，组合物和试剂盒。 特别地，描述了用于生物素的放射性标记的方法以及相关的化合物。 还讨论了在预定靶方法中有用的制造条款。
-
7.发明授权Stable therapeutic radionuclide compositions and methods for preparation thereof 失效稳定的治疗放射性核素组合物及其制备方法
公开(公告)号：US5393512A
公开(公告)日：1995-02-28
申请号：US124359
申请日：1993-09-20
IPC分类号： A61K51/04 , A61K51/10 , A61K51/12 , C07C227/08 , C07C271/22 , A61K43/00 , A61K49/02
CPC分类号： C07C271/22 , A61K51/048 , A61K51/1093 , A61K51/12 , B82Y5/00 , C07C227/08 , A61K2123/00
摘要： Stable therapeutic radionuclide compositions comprising, for example, .sup.186 Re, .sup.188 Re and .sup.131 I stably bound to a proteinaceous targeting moiety and suitable for human in vivo administration are disclosed. Stabilizing agents preferably comprise antioxidants and challenging agents, and combination of HSA with an antioxidant and/or challenging agent provides enhanced long term stability. Ascorbic acid is an especially preferred stabilizing agent, which provides stability of therapeutic radionuclide compositions at levels of at least about 90% for several hours up to several days.
摘要翻译： 公开了稳定的治疗放射性核素组合物，其包含例如稳定结合蛋白质靶向部分并适于人体内施用的186Re，188Re和131I。 稳定剂优选包含抗氧化剂和挑战性试剂，并且HSA与抗氧化剂和/或挑战性试剂的组合提供增强的长期稳定性。 抗坏血酸是一种特别优选的稳定剂，其在至少约90％的水平下提供几个小时至几天的治疗性放射性核素组合物的稳定性。
-
公开(公告)号：US4990787A
公开(公告)日：1991-02-05
申请号：US416221
申请日：1989-09-29
申请人： Jean-Luc Vanderheyden , Fu-Min Su
发明人： Jean-Luc Vanderheyden , Fu-Min Su
IPC分类号： A61K51/12
CPC分类号： A61K51/1282 , A61K2121/00 , G21G1/0005
摘要： Improved radionuclide generators include a substantially insoluble salt of a parent radionuclide precursor which may be directly irradiated and then packed in a column for subsequent elution of the daughter radionuclide without the production of counter ion isotopic contaminants. The parent radionuclide precursor is provided in the form of an insoluble salt of the parent element whose counter ion, preferably aluminum, forms a relatively soluble salt with the desired daughter radionuclide. The improved generators may be prepared by reacting a parent radionuclide precursor with aluminum to obtain an aluminum salt of the precursor having low solubility in water, irradiating the aluminum salt to obtain an irradiated aluminum salt of the parent radionuclide, and then disposing the irradiated parent radionuclide in an elutable container. Useful parent radionuclide precursors include molybdenum-98 in the form of molybdate for the production of daughter .sup.99m Tc, as soluble pertechnetate, and tungsten-186 in the form of tungstate for the production of daughter .sup.188 Re as soluble perrhenate. The daughter .sup.99m Tc or .sup.188 Re may be eluting the generator matrix, e.g., with a saline solution.
摘要翻译： 改进的放射性核素发生器包括母体放射性核素前体的基本上不溶的盐，其可以直接照射，然后包装在柱中，随后洗脱子内放射性核素而不产生抗衡离子同位素污染物。 母体放射性核素前体以母体元素的不溶性盐的形式提供，其抗衡离子，优选为铝，与所需的儿子放射性核素形成相对可溶的盐。 可以通过使母体放射性核素前体与铝反应来制备改进的发生器，以获得在水中具有低溶解度的前体的铝盐，照射铝盐以获得母体放射性核素的照射的铝盐，然后将照射的母体放射性核素 在可洗涤的容器中。 有用的母体放射性核素前体包括钼酸盐形式的钼-98，用于生产作为可溶性高锝酸盐的子体99mTc，钨酸盐形式的钨-186用于生产可溶性高铼酸盐的子188Re。 子母99mTc或188Re可以例如用盐水溶液洗脱发生器基质。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.029 秒)
